3158University of Alberta, Edmonton, Alberta, Canada.
6363University of Ottawa, Ottawa, Ontario, Canada.
Healthc Manage Forum. 2020 Sep;33(5):228-232. doi: 10.1177/0840470420932185. Epub 2020 Jun 18.
Recently, both the Canadian and provincial governments have instituted policies to reduce manufacturers' prices for generic ($250 million sales annually) and brand name ($1,300 million sales annually) drugs. Both government groups made estimates of the financial magnitude of changes in drug prices, but neither has estimated the impact on retail pharmacies. We used a Cost-Volume-Profit model combined with operational data collected nationally to estimate the national impact of the pricing policy changes on pharmacy gross profits. Results show the average value of gross profits per pharmacy per year was approximately $440,000. It is estimated that the policy changes will lead to a 6.8% reduction in gross profits. Adding reductions in rebates for generic drugs, the pharmacies' reductions in gross profits will be 7.2%. In conclusion, policy-makers often ignore how their pricing changes influence the financial position of pharmacies, even though the impact can be substantial.
最近,加拿大联邦和省政府都制定了政策,以降低仿制药(年销售额 2.5 亿美元)和品牌药(年销售额 13 亿美元)制造商的价格。这两个政府部门都对药品价格变化的财务影响进行了估计,但都没有估计对零售药店的影响。我们使用成本-量-利模型,并结合全国范围内收集的运营数据,来估计定价政策变化对药店总利润的全国性影响。结果表明,每家药店每年的平均总利润约为 44 万美元。据估计,政策变化将导致总利润减少 6.8%。加上仿制药回扣的减少,药店的总利润将减少 7.2%。总之,政策制定者往往忽略了他们的定价变化如何影响药店的财务状况,尽管这种影响可能是巨大的。